# CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct05722418/  
OnCo record `nct05722418` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CB-011 run by Caribou Biosciences, Inc., now recruiting.

## Summary

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT05722418 by Caribou Biosciences, Inc., with 50 participants planned, started 2023-02-06. Conditions recorded: Relapsed/Refractory Multiple Myeloma. Interventions recorded: CB-011.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05722418
- Phase: 1
- Setting: A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
- Sponsor: Caribou Biosciences, Inc.
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT05722418: https://clinicaltrials.gov/study/NCT05722418

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [CB-011](https://onco.cc/drugs/cb-011/)
- companies: [Caribou Biosciences](https://onco.cc/companies/caribou/)

---
JSON: https://onco.cc/api/v1/entities/nct05722418.json